FDA flags Wegovy ad as misleading, orders corrective actions
TL;DR Summary
The FDA says Novo Nordisk’s Wegovy TV ad makes false or misleading claims, overstating benefits and not adequately presenting risks, and it calls for immediate corrective action that could include halting the ads; the move comes as Novo battles Eli Lilly and copycats in the GLP-1 obesity market, with Wegovy gaining adopters since its January launch.
- FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims CNBC
- Novo’s Obesity Pill TV Ad Includes Misleading Claims, FDA Says Bloomberg.com
- US FDA says Novo's obesity pill TV ad is false or misleading Reuters
- Novo Nordisk stock pares gains to 4% after FDA flags misleading Wegovy ad By Investing.com Investing.com South Africa
- FDA says Novo's obesity pill TV Ad is false or misleading marketscreener.com
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
2 min
vs 3 min read
Condensed
89%
507 → 56 words
Want the full story? Read the original article
Read on CNBC